ConductScience.org, home
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
API referenceFor AI assistants

Trial · NCT03162796

Results by group1,631

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 1,631

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24Placebo22.2percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24Guselkumab 100 mg q8w52.0percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24Guselkumab 100 mg q4w59.4percentage of participants
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24Placebo-0.074395% Confidence Interval -0.1605 to 0.0119units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24Guselkumab 100 mg q8w-0.322595% Confidence Interval -0.4082 to -0.2369units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24Guselkumab 100 mg q4w-0.396895% Confidence Interval -0.4825 to -0.3112units on a scale
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 24Placebo8.7percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 24Guselkumab 100 mg q8w29.9percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 24Guselkumab 100 mg q4w35.9percentage of participants
Percentage of Participants With Psoriasis Response of IGA (Score: 0[Cleared] or 1[Minimal] and >=2 Grade Reduction From Baseline) at Week 24 Among Participants With >=3% Body Surface Area (BSA) Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline
Placebo15.4percentage of participants
Percentage of Participants With Psoriasis Response of IGA (Score: 0[Cleared] or 1[Minimal] and >=2 Grade Reduction From Baseline) at Week 24 Among Participants With >=3% Body Surface Area (BSA) Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline
Guselkumab 100 mg q8w57.3percentage of participants
Percentage of Participants With Psoriasis Response of IGA (Score: 0[Cleared] or 1[Minimal] and >=2 Grade Reduction From Baseline) at Week 24 Among Participants With >=3% Body Surface Area (BSA) Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline
Guselkumab 100 mg q4w75.3percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16Placebo25.4percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16Guselkumab 100 mg q8w52.0percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16Guselkumab 100 mg q4w60.2percentage of participants
Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24Placebo-0.7095% Confidence Interval -0.89 to -0.51units on a scale
Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24Guselkumab 100 mg q8w-1.4395% Confidence Interval -1.61 to -1.24units on a scale
Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24Guselkumab 100 mg q4w-1.6195% Confidence Interval -1.80 to -1.42units on a scale
Percentage of Participants Who Achieve an American College of Rheumatology (ACR) 70 Response at Week 24Placebo5.6percentage of participants
Percentage of Participants Who Achieve an American College of Rheumatology (ACR) 70 Response at Week 24Guselkumab 100 mg q8w11.8percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03162796/results

API referenceFor AI assistants